Guide to marketing medical cannabis in Europe

Medical cannabis is a massively growing market in Europe – but it is not classified or regulated within the usual framework for medicines. There is a lack of European regulations, intended to harmonize marketing of medicines, for either CBD or THC-based cannabis products.

Yet, the reality is that medical cannabis has shown efficacy in trials and is being deployed legally in medical settings as a therapeutic for conditions ranging from cancer to AIDS
Major global cannabis exporters, including those from Canada and North America, cannot tap into a common regulatory pathway to European markets.

Cannabis is a massive opportunity, but supplying the different European markets can be a
challenge. To help address the challenge, Arriello has produced this country-by-country guide to the patchwork of regulations across Europe.


Example – Pennsylvania has approved cannabis use for these conditions: Amyotrophic Lateral Sclerosis;
Crohn’s disease;
Damage to the nervous tissue of the spinal
cord with objective neurological indication of
intractable spasticity;
HIV (Human Immunodeficiency Virus)/AIDS
(Acquired Immune Deficiency Syndrome);
Huntington’s disease;

Inflammatory Bowel disease;
Intractable seizures;
Multiple sclerosis;
Parkinson’s disease;
Post-traumatic stress disorder;
Severe chronic or intractable pain of neuropathic
origin or severe chronic or intractable pain in which conventional therapeutic intervention and opiate therapy is contraindicated or  neffective;
Sickle cell anemia.

Free Download PDF

Continue at:

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:


Manostaxx – Industrial Management Consulting

Leave a Reply

Your email address will not be published. Required fields are marked *